682
Background:
In the United States, >170,000 individuals are living with metastatic breast cancer (mBC). New treatments continue to emerge and vary by mode of delivery, length, side effects, and costs. While providers share information about potential risks and benefits of different treatments, accounting for...
Laura C. Pinheiro, Z. Hamilton, Darima Dorzhieva et al.· JCO Oncology Practice· 0 citations
Despite established NCCN guidelines, disparities in guideline-concordant care persist in metastatic breast cancer (mBC). We examined first-line Category 1 systemic therapy concordance and time to treatment to characterize equity gaps at an academic medical center.
In the PRISM (Precision Oncology Risk Iden...
Drew Neish, T. Akinyemiju, Ashwini R. Joshi et al.· Cancer Epidemiology, Biomark...· 0 citations
Introduction Existing research has linked increased patient participation in oncology care to greater patient satisfaction, enhanced quality of life, and improved healthcare utilization among patients with cancer. Yet, current measures of patient engagement and similar constructs do not reflect the unique experiences o...
Carolyn Hagler, S. Kircher, Guisselle A. Wismer et al.· Frontiers in Oncology· 0 citations
INTRODUCTION
For patients with advanced/metastatic non-small cell lung cancer (aNSCLC) without actionable genomic alterations (AGAs) and with programmed death-ligand 1 (PD-L1) ≥ 50%, first-line (1L) treatment options include immunotherapy (IO) monotherapy or IO with chemotherapy. However, real-world data describing tre...
D. Owen, Martin Sebastian, H. Kenmotsu et al.· Oncology and Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
